Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Vasopressors and Enteral Nutrition in the Survival Rate of Children During Extracorporeal Membrane Oxygenation
Alexander, Erin , Absah, Imad , Steien, Dana B., Grothe, Rayna, Crow, Sheri

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | June 1, 2022 | Volume: 75 | Issue: 3 | Pages: 340-344

10.1097/mpg.0000000000003496 | PMID 35641894 Get It

Objectives:Nutrition support is essential in improving outcome and survival in children on extra corporal membranous support (ECMO). We aim to evaluate the association between the timing of enteral nutrition (EN) initiation and its impact on outcome.Methods:We retrospectively reviewed the electronic health records of children (≤18 years) from November 2014 to November 2019 who were on veno‐arterial ECMO for ≥48 hours. Abstracted data included demographics, ECMO indication and duration, timing of EN initiation, change in weight‐for‐age z score (WAZ), and survival rate. The vasoactive‐inotropic score (VIS) was calculated to assess illness acuity.Results:We identified 76 children with median age (interquartile range [IQR]) of 0.3 years (0–2.6), 46 of which were infants (59%) who required ECMO for a median (IQR) of 10 days (6–22). Thirty‐six (47%) survived to hospital discharge. EN was initiated in 55 (72%) of patients while on ECMO. EN initiation by day 3 of ECMO was positively associated with survival (P = 0.0438). VIS at the time of EN initiation was lower in surviving infants (P = 0.022). Children who achieved enteral autonomy were more likely to survive (P = 0.0024). Survivors had greater WAZs at ECMO completion (P = 0.0004).Conclusions:Initiation of EN by day 3 of ECMO and at a lower VIS is associated with greater likelihood of survival.
Smoldering giant cell arteritis in a coronary artery
Kaymakci, Mahmut , Alexander, Mariam P., Warrington, Kenneth J. , Warrington, Kenneth J , Kaymakci, Mahmut S , Elfishawi, Mohanad , Koster, Matthew J.

Mayo Clinic

Rheumatology | May 31, 2022 | Volume: 61 | Issue: 12 | Pages: e384-e385

10.1093/rheumatology/keac321 | PMID 35640112 Get It

Bioresorbable flow diverters for the treatment of intracranial aneurysms: review of current literature and future directions
Oliver, Alexander A , Carlson, Kent, Bilgin, Cem , Larco, Jorge Arturo , Kadirvel, Ramanathan , Daescu, Dan Dragomir, Kallmes, David F. , Carlson, Kent D, Arturo Larco, Jorge L , Dragomir Daescu, Dan, Oliver, Alexander A , Guillory, Roger J.

Mayo Clinic

Journal of NeuroInterventional Surgery | May 30, 2022 | Volume: 15 | Issue: 2 | Pages: 178-182

10.1136/neurintsurg-2022-018941 | PMID 35636949 Get It

The use of flow diverters is a rapidly growing endovascular approach for the treatment of intracranial aneurysms. All FDA-approved flow diverters are composed of nitinol or cobalt-chromium, which will remain in the patient for the duration of their life. Bioresorbable flow diverters have been proposed by several independent investigators as the next generation of flow diverting devices. These devices aim to serve their transient function of occluding and healing the aneurysm prior to being safely resorbed by the body, eliminating complications associated with the permanent presence of conventional flow diverters. Theoretical advantages of bioresorbable flow diverters include (1) reduction in device-induced thrombosis; (2) reduction in chronic inflammation and device-induced stenosis; (3) reduction in side branch occlusion; (4) restoration of physiological vasomotor function; (5) reduction in imaging artifacts; and (6) use in pediatric applications. Advances made in the similar bioresorbable coronary stenting field highlight some of these advantages and demonstrate the feasibility and safety of bioresorbable endovascular devices in the clinic. The current work aims to review the progress of bioresorbable flow diverters, identify opportunities for further investigation, and ultimately stimulate the advancement of this technology.
Use of a Viral Filter to Reduce Exposure to Exhaled Aerosol Does Not Affect Methacholine Dose Delivery During Bronchoprovocation Testing
Subat, Yosuf W., Meyer, Todd J., Torgerud, Keith D, Scanlon, Paul D., Lim, Kaiser G. , Niven, Alexander S.

Mayo Clinic

Respiratory Care | May 24, 2022 | Volume: 67 | Issue: 8 | Pages: 899-905

10.4187/respcare.09703 | PMID 35610032 Get It

BACKGROUND: Methacholine challenge testing (MCT) is a common bronchoprovocation technique used to assess airway hyper-responsiveness. We previously demonstrated that the addition of a viral filter to the nebulizer exhalation limb substantially reduced expelled particles during MCT. Our aim was to evaluate whether this modification affects the delivered dose of methacholine. METHODS: A mechanical ventilator was connected to a lung simulator with breathing frequency 15 breaths/min, tidal volume 500 mL, inspiratory-expiratory ratio 1:1, with a sinusoidal waveform. We compared methacholine dose delivery using the Hudson Micro Mist or AeroEclipse II BAN nebulizers powered by either a dry gas source or a compressor system. A filter placed in line between the nebulizer and test lung was weighed before and after 1 min of nebulized methacholine delivery. Mean inhaled mass was measured with and without a viral filter on the exhalation limb. Dose delivery was calculated by multiplying the mean inhaled mass by the respirable fraction (particles < 5 μm) and inhalation time. Unpaired t test was used to compare methacholine dose delivery with and without viral filter placement. RESULTS: The addition of a viral filter did not significantly affect methacholine dose delivery across all devices tested. Using a 50-psi dry gas source, dose delivered with or without a viral filter did not differ with the Hudson (422.3 μg vs 282.0 μg, P = .11) or the AeroEclipse nebulizer (563.0 μg vs 657.6 μg, P = .59). Using the compressor, dose delivered with and without a viral filter did not differ with the Hudson (974.0 μg vs 868.0 μg, P = .03) or the AeroEclipse nebulizer (818.0 μg vs 628.5 μg, P = .42). CONCLUSIONS: The addition of a viral filter to the nebulizer exhalation limb did not affect methacholine dose during bronchoprovocation testing. Routine use of a viral filter should be considered to improve pulmonary function technician safety and infection control measures during the ongoing COVID-19 pandemic.
Paroxysmal supine hypoxaemia with hyperthyroidism and atrial fibrillation: a case report of a diagnostic challenge
Liu, Liang Yen , Reddy, Yogesh N.V. , Niven, Alexander S. , Hu, Tiffany , Mulpuru, Siva K. , Cullen, Michael W. , Hu, Tiffany Y, Larson, Kathryn F. , Nishimura, Rick , Niven, Alexander S

Mayo Clinic

European Heart Journal - Case Reports | May 24, 2022 | Volume: 6 | Issue: 6 | Pages: No page available

10.1093/ehjcr/ytac214 | PMID 35734629 Get It

Abstract Background A patent foramen ovale (PFO) is a persistent embryonic defect in the interatrial septum. Platypnoea-orthodeoxia syndrome is characterized by positional hypoxaemia that is most commonly due to right-to-left shunting through a PFO. Dynamic right-to-left shunting through a PFO can also exacerbate positional hypoxaemia without platypnea-orthodeoxia syndrome. Case summary A 78-year-old woman with hyperthyroidism and paroxysmal atrial fibrillation (AF) presented with positional hypoxaemia exacerbated by supine positioning. Diagnostic testing revealed intermittent right-to-left shunting through a PFO triggered by worsening atrial functional tricuspid regurgitation and elevated right atrial pressures. Diuresis, rate control, and thyroidectomy initially led to resolution of positional hypoxaemia, but recurrent AF episodes triggered right-to-left shunting with recurrent desaturation. Left atrial and cavo-tricuspid isthmus ablation led to restoration of normal sinus rhythm and resolution of positional hypoxaemia without PFO closure. Discussion The clinical presentation of intermittent intracardiac right-to-left shunting can mimic decompensated heart failure with pulmonary oedema. Persistent hypoxaemia out of proportion to the degree of pulmonary oedema and minimally responsive to supplemental O2 should raise suspicion for right-to-left shunt aetiology. Positional arterial blood gases can facilitate the diagnostic evaluation of refractory hypoxaemia in cases of suspected shunting. Diagnostic imaging for PFO detection includes both transthoracic and transesophageal echocardiography with Valsalva manoeuver and agitated saline injection. Closure of a PFO for management of arterial deoxygenation syndromes should not be performed before treating other causes of arterial deoxygenation and optimizing factors that may exacerbate shunting across the PFO.
Automated Microfluidic System with Active Mixing Enables Rapid Analysis of Biomarkers in 5 μL of Whole Blood
Gonzalez‐Suarez, Alan M. , Carey, William A., Revzin, Alexander , Revzin, Alexander , Gonzalez-Suarez, Alan M , Stybayeva, Gulnaz

Mayo Clinic

Analytical Chemistry | May 23, 2022 | Volume: 94 | Issue: 27 | Pages: 9706-9714

10.1021/acs.analchem.2c01139 | PMID 35604796 Get It

The Development of Novel Drug Treatments for Stroke Patients: A Review
Frank, Dmitry , Boyko, Matthew , Gruenbaum, Benjamin F. , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich

Mayo Clinic

International Journal of Molecular Sciences | May 21, 2022 | Volume: 23 | Issue: 10 | Pages: 5796

10.3390/ijms23105796 | PMID 35628606 Get It

Acute ischemic stroke is a critical condition that can result in disability and death. The consequences of this medical condition depend on various factors, including the size of the stroke, affected brain region, treatment onset, and the type of treatment. The primary objective of stroke treatment is to restart ischemic penumbra tissue perfusion and reduce infarct volume by sustaining blood flow. Recent research on the condition’s pathological pathways and processes has significantly improved treatment options beyond restoring perfusion. Many studies have concentrated on limiting injury severity via the manipulation of molecular mechanisms of ischemia, particularly in animal research. This article reviews completed and ongoing research on the development of acute ischemic stroke drugs. This study focuses on three main categories of antithrombotic drugs, thrombolytic drugs, and neuroprotective agents. The paper outlines findings from animal and clinical trials and explores the working mechanisms of these drugs.
Glutamate Efflux across the Blood–Brain Barrier: New Perspectives on the Relationship between Depression and the Glutamatergic System
Gruenbaum, Benjamin F. , Frenkel, Amit , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Frenkel, Amit , Boyko, Matthew , Zlotnik, Alexander Anatolievich , Fleidervish, Ilya A.

Mayo Clinic

Metabolites | May 20, 2022 | Volume: 12 | Issue: 5 | Pages: 459

10.3390/metabo12050459 | PMID 35629963 Get It

Depression is a significant cause of disability and affects millions worldwide; however, antidepressant therapies often fail or are inadequate. Current medications for treating major depressive disorder can take weeks or months to reach efficacy, have troubling side effects, and are limited in their long-term capabilities. Recent studies have identified a new set of glutamate-based approaches, such as blood glutamate scavengers, which have the potential to provide alternatives to traditional antidepressants. In this review, we hypothesize as to the involvement of the glutamate system in the development of depression. We identify the mechanisms underlying glutamate dysregulation, offering new perspectives on the therapeutic modalities of depression with a focus on its relationship to blood–brain barrier (BBB) permeability. Ultimately, we conclude that in diseases with impaired BBB permeability, such as depression following stroke or traumatic brain injury, or in neurogenerative diseases, the glutamate system should be considered as a pathway to treatment. We propose that drugs such as blood glutamate scavengers should be further studied for treatment of these conditions.
Utility of Biomarkers for Sepsis-Associated Acute Kidney Injury Staging
Molinari, Luca , Smith, A.J. Conrad , Landsittel, Douglas , Singbartl, Kai , Yealy, Donald M., Kellum, John A. , Investigators, ProCESS and ProGReSS-AKI, Keener, Christopher, Lucko, Nicole, Pike, Francis, Yende, Sachin , Gimbel, Elizabeth, Landis, Kyle, Stapleton, Diana K., Weissfeld, Lisa A., Willochell, Michael, Wofford, Kourtney A., Watts, Hannah , Venkat, Arvind , Hou, Peter C. , Massaro, Anthony F., Parmar, Siddharth , Brewer, Kori L. , Delbridge, Theodore R. , Mainhart, Allison, Miner, James R. , Allen, Todd L., Grissom, Colin K. , Swadron, Stuart P., Carlson, Richard, LoVecchio, Frank , Parry, Blair A. , Ellender, Timothy J., Sama, Andrew E., Fine, Jonathan , Nafeei, Soheil, Wojnar, Margaret, Pearl, Ronald G. , Wilber, Scott T., Sinert, Richard , Orban, David J., Ufberg, Jacob W. , Albertson, Timothy, Panacek, Edward A., Parekh, Sohan, Gunn, Scott R. , Rittenberger, Jon S., Wadas, Richard J. , Edwards, Andrew R., Holmes, T., Weinert, Craig , Harris, Estelle S. , Self, Wesley H. , Dubinski, Diane, Phillips, Carolyn, Migues, Ronald M., Singbartl, Kai , Kellum, John A , Rio‐Pertuz, Gaspar Del , Palevsky, Paul M. , Chawla, Lakhmir S. , Huang, David T. , Angus, Derek C. , Investigators, ProCESS and ProGReSS-AKI, Barnato, Amber E. , Eaton, Tammy L. , Kulstad, Erik Benjamin , Limkakeng, Alexander T. , Conrad, Steven A. , Bajwa, Ednan K. , Filbin, Michael R. , Terndrup, Thomas E. , Wilson, Jason W. , Kelly, Matthew, Wang, Henry E. , McCurdy, Michael T. , Phillips, Carolyn A

Mayo Clinic

JAMA Network Open | May 18, 2022 | Volume: 5 | Issue: 5 | Pages: e2212709

10.1001/jamanetworkopen.2022.12709 | PMID 35583867 Get It